BENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT
The present invention relates to a benzamide derivative, a method for preparing same, and a pharmaceutical composition for the prevention or treatment of cancer, containing same as an active ingredient. The benzamide derivative according to an aspect of the present invention can be used in the preve...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre ; kor |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The present invention relates to a benzamide derivative, a method for preparing same, and a pharmaceutical composition for the prevention or treatment of cancer, containing same as an active ingredient. The benzamide derivative according to an aspect of the present invention can be used in the prevention or treatment of cancer by suppressing EGFR mutation, and, when administered in combination with an EGFR antagonist such as cetuximab, exhibits a significantly synergistic effect on anticancer activity, and thus can be effectively used as an anticancer agent.
La présente invention concerne un dérivé de benzamide, un procédé de préparation associé, et une composition pharmaceutique pour la prévention ou le traitement du cancer, le contenant en tant que principe actif. Le dérivé de benzamide selon un aspect de la présente invention peut être utilisé dans la prévention ou le traitement du cancer par suppression de la mutation de l'EGFR, et, lorsqu'il est administré en combinaison avec un antagoniste de l'EGFR tel que le cétuximab, présente un effet synergique significatif sur l'activité anticancéreuse, et peut donc être efficacement utilisé en tant qu'agent anticancéreux.
벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물에 관한 것으로, 본 발명의 일 측면에서 제공하는 벤즈아미드 유도체는 EGFR 돌연변이를 억제하여 암의 예방 또는 치료에 사용될 수 있고, 세툭시맙(Cetuximab) 등의 EGFR 길항제와 병용투여될 경우 항암활성 측면에서 현저한 상승(synergy) 효과가 나타나 항암제로 유용하게 사용될 수 있다. |
---|